Skip to main content
AAN.com

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004;63:2280–2287.
2.
Kikuchi T, Nomura M, Tomita H, et al. Paroxysmal kinesigenic choreoathetosis (PKC): confirmation of linkage to 16p11-q21, but unsuccessful detection of mutations among 157 genes at the PKC-critical region in 7 PKC families. J Hum Genet 2007;52:334–341.
3.
Lipton J, Rivkin MJ. 16p11.2-related paroxysmal kinesigenic dyskinesia and dopa-responsive parkinsonism in a child. Neurology 2009;73:479–480.
4.
Van Bogaert P, Azizieh R, Desir J, et al. Mutation of a potassium channel-related gene in progressive myoclonic epilepsy. Ann Neurol 2007;61:579–586.
5.
Wittmack EK, Rush AM, Hudmon A, Waxman SG, Dib-Hajj SD. Voltage-gated sodium channel Nav1.6 is modulated by p38 mitogen-activated protein kinase. J Neurosci 2005;25:6621–6630.
6.
Weiss LA, Shen Y, Korn JM, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008;358:667–675.

Information & Authors

Information

Published In

Neurology®
Volume 77Number 14October 4, 2011
Pages: 1401-1402
PubMed: 21940615

Publication History

Received: April 11, 2011
Accepted: June 14, 2011
Published online: September 21, 2011
Published in print: October 4, 2011

Permissions

Request permissions for this article.

Funding Information

Disclosure: Dr. Dale has received grant funding from the National Health and Medical Research Council, University of Sydney, Star Scientific Foundation, and Tourette Syndrome Association; has received honoraria from Biogen-Idec; serves on a scientific advisory board for the Brisbane Children's Hospital; receives publishing royalties for Autoimmune and Inflammatory Disorders of the Nervous System in Children (Mac Keith Press, 2009); and has received research support from the American Tourette Syndrome Association and the Brain Foundation. Dr. Grattan-Smith reports no disclosures. Dr. Fung serves on scientific advisory boards for Abbott, Allergan, Inc., Boehringer Ingelheim, Hospira, Inc., Ipsen, Lundbeck Inc., Novartis, Solvay Pharmaceuticals, Inc., and UCB; has received funding for travel or speaker honoraria from Boehringer Ingelheim and Ipsen; serves on the editorial boards of Movement Disorders, ACTA Neuropsychiatrica, and Basal Ganglia; and receives research support from NH&MRC. Dr. Peters has received research support from Royal College of Pathologists, Australia, Human Genetics Society of Australasia, Genetics Society of Australasia, and Australasian Society of Cytogeneticists.

Authors

Affiliations & Disclosures

Russell C. Dale, PhD
From the Movement Disorder Clinic (R.C.D., P.G.-S.), Institute of Neuroscience and Muscle Research, and Department of Cytogenetics (G.B.P.), the Children's Hospital at Westmead, University of Sydney, Sydney; and Movement Disorders Unit (V.S.C.F.), Department of Neurology, Westmead Hospital and Sydney Medical School, The University of Sydney, Sydney, Australia.
Padraic Grattan-Smith, FRACP
From the Movement Disorder Clinic (R.C.D., P.G.-S.), Institute of Neuroscience and Muscle Research, and Department of Cytogenetics (G.B.P.), the Children's Hospital at Westmead, University of Sydney, Sydney; and Movement Disorders Unit (V.S.C.F.), Department of Neurology, Westmead Hospital and Sydney Medical School, The University of Sydney, Sydney, Australia.
Victor S.C. Fung, PhD
From the Movement Disorder Clinic (R.C.D., P.G.-S.), Institute of Neuroscience and Muscle Research, and Department of Cytogenetics (G.B.P.), the Children's Hospital at Westmead, University of Sydney, Sydney; and Movement Disorders Unit (V.S.C.F.), Department of Neurology, Westmead Hospital and Sydney Medical School, The University of Sydney, Sydney, Australia.
Greg B. Peters, PhD
From the Movement Disorder Clinic (R.C.D., P.G.-S.), Institute of Neuroscience and Muscle Research, and Department of Cytogenetics (G.B.P.), the Children's Hospital at Westmead, University of Sydney, Sydney; and Movement Disorders Unit (V.S.C.F.), Department of Neurology, Westmead Hospital and Sydney Medical School, The University of Sydney, Sydney, Australia.

Notes

Address correspondence and reprint requests to Dr. Russell Dale, Clinical School, Children's Hospital at Westmead, Locked Bag 4001, NSW 2145, Australia; [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Episodic ataxia in child with 16p11.2 deletion including PRRT2, Parkinsonism & Related Disorders, 118, (105955), (2024).https://doi.org/10.1016/j.parkreldis.2023.105955
    Crossref
  2. Paroxysmal Kinesigenic Dyskinesia Caused by 16p11.2 Microdeletion and Related Clinical Features, Neurology Genetics, 8, 2, (2022)./doi/10.1212/NXG.0000000000000659
    Abstract
  3. Clinical and genetic analyses of 150 patients with paroxysmal kinesigenic dyskinesia, Journal of Neurology, 269, 9, (4717-4728), (2022).https://doi.org/10.1007/s00415-022-11103-0
    Crossref
  4. Translating Genetic Discovery into a Mechanistic Understanding of Pediatric Movement Disorders: Lessons from Genetic Dystonias and Related Disorders, Advanced Genetics, 4, 2, (2022).https://doi.org/10.1002/ggn2.202200018
    Crossref
  5. The clinical and genetic spectrum in infants with (an) unprovoked cluster(s) of focal seizures, European Journal of Paediatric Neurology, 24, (148-153), (2020).https://doi.org/10.1016/j.ejpn.2019.12.003
    Crossref
  6. PRRT2-related phenotypes in patients with a 16p11.2 deletion, European Journal of Medical Genetics, 62, 4, (265-269), (2019).https://doi.org/10.1016/j.ejmg.2018.08.002
    Crossref
  7. PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype–phenotype correlation reanalysis in literatures, International Journal of Neuroscience, 128, 8, (751-760), (2018).https://doi.org/10.1080/00207454.2017.1418345
    Crossref
  8. Benign nocturnal alternating hemiplegia of childhood: A clinical and nomenclatural reappraisal, European Journal of Paediatric Neurology, 22, 6, (1110-1117), (2018).https://doi.org/10.1016/j.ejpn.2018.07.012
    Crossref
  9. 16p11.2 deletion in patients with paroxysmal kinesigenic dyskinesia but without intellectual disability, Brain and Behavior, 8, 11, (2018).https://doi.org/10.1002/brb3.1134
    Crossref
  10. Benign infantile seizures followed by autistic regression in a boy with 16p11.2 deletion, Epileptic Disorders, 19, 2, (222-225), (2017).https://doi.org/10.1684/epd.2017.0909
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share